In addition to single agent activity, anti-mouse CTLA-4 antibodies have shown compelling anti-tumor efficacy in combination with other immunomodulatory antibodies, therapeutic vaccines and cell therapies, thereby supporting the versatility of neutralizing the CTLA-4 pathway to promote successful cancer immunotherapy [13]. Here, CTLA4 is linked to neoplasm.